BioCentury
ARTICLE | Company News

Amryt gets exclusive license to gene therapy platform

March 16, 2018 6:07 PM UTC

The University College Dublin (Dublin, Ireland) granted Amryt Pharma plc (LSE:AMYT) exclusive rights to a non-viral gene therapy platform. The technology uses High-Branched Poly (beta-amino ester) (HPAE) polymer technology to deliver gene therapies.

Amryt is using the technology initially to develop a topical treatment for recessive dystrophic epidermolysis bullosa (RDEB). The company said that preclinical data has shown that the therapy increased levels of collagen VII in the skin of a xenograft model of the disease. Amryt plans to report data from additional preclinical testing of the therapy to treat RDEB in 4Q18...